TMC
ARCT icon

Trellus Management Company’s Arcturus Therapeutics ARCT Stock Holding History

Trellus Management Company’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,571
Closed -$386K – 83
2014
Q3 		$386K Buy
+3,571
New +$465K 0.33% 74

Other funds holding ARCT

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Trellus Management Company's ARCT Position: Q4 2014 in Review

Trellus Management Company sold out of Arcturus Therapeutics (ARCT) in Q4 2014, closing a stake of 7,169 shares — an estimated $775K sold.

Trellus Management Company first reported a position in ARCT in Q2 2013 and held it in 6 quarters. The position peaked at $955K in Q2 2014. 28 funds tracked by Wall St. Rank hold ARCT as of Q4 2014.

  • Trellus Management Company reported no remaining Arcturus Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Trellus Management Company sold 7,169 Arcturus Therapeutics shares in Q4 2014, an estimated $775K.
  • Trellus Management Company first reported a position in Arcturus Therapeutics in Q2 2013 and held it in 6 quarters.
  • Trellus Management Company's Arcturus Therapeutics position peaked at $955K in Q2 2014.
  • 28 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2014.

Based on Trellus Management Company's 13F filing for Q4 2014, filed 13 Feb 2015.